Vaginal dysbiosis and HPV: restoring balance to help prevent cervical cancer?

The vaginal microbiota, dominated by lactobacilli, seems to play a crucial protective role against HPV and cervical cancer. Could new therapeutic approaches through probiotics help prevent cervical cancer and improve gynecological health?

The vaginal microbiota is receiving growing attention because of its implications for women’s health.
In January 2026, a Mexican research team 1published, a review of the vaginal microbiota and its role in various conditions, particularly cervical cancer and the risk of HPV-associated cervical lesions. 

10¹⁰ The vagina hosts approximately 10¹⁰ to 10¹¹ microorganisms. ¹

9 % Of the total human microbiota, the urogenital region (which includes the vagina) accounts for approximately 9% of the overall composition. ¹

Protected by lactobacilli

The vaginal microbiota is marked by low diversity. It is generally dominated by lactobacilli, especially L. crispatus, L. jensenii, L. gasseri and L. iners. These lactobacilli help maintain vaginal health, protect against pathogens and regulate inflammation, for example by competing for nutrients, producing bacteriocins, modulating the immune system and reducing vaginal pH. 

4

A healthy vaginal microbiota is generally dominated by one of 4 Lactobacillus species:

  • L. crispatus
  • L. jensenii
  • L. gasseri
  • and L. iners.

Conversely, high microbial diversity is associated with an increased risk of sexually transmitted infections, pelvic inflammatory disease, pregnancy complications (infertility, premature birth, low birth weight) and infection with human papillomavirus (HPV),increasing the risk of progression to an HPV-related cervical lesion.

4

Cervical cancer is the fourth most common cancer in women globally with around 660,000 new cases and around 350,000 deaths in 2022. 
This uterine cancer is a major issue for women. 2

Vaginal microbiota and HPV

In the specific case of HPV, vaginal dysbiosis promotes viral progression by creating a pro-inflammatory environment.
The reduction in lactobacilli and the proliferation of anaerobic bacteria (Gardnerella, Sneathia, Atopobium) inhibit apoptosis, increase inflammatory cytokines and raise pH. These changes all make it easier for HPV to become established in the cervix and adjacent uterine tissue. 

Conversely, a microbiota rich in lactobacilli is associated with a less inflammatory microenvironment. According to some studies, it may modulate the expression of the viral oncoproteins E6/E7 in infected cells. This context is associated also with more favorable HPV clearance and may help limit progression to cervical lesions. 

In addition, excision of precancerous cervical lesions induces a change in the composition of the vaginal microbiota only in women who clear HPV, with a shift from pathogenic bacteria (Prevotella, Sneathia) to protective lactobacilli (L. iners then L. crispatus). By contrast, in cases of persistent HPV, no change appears. 
 

90-70-90

Countries around the world are accelerating efforts to eliminate cervical cancer, guided by the global 90–70–90 targets :

  • 90% of girls fully vaccinated with HPV vaccine by age 15,
  • 70% of women screened by ages 35 and 45,
  • and 90% of women with pre-cancer or invasive cancer receiving appropriate treatment.

Illustrating the importance of screening, vaccination and treatment in prevention for women’s health. 2

Finally, probiotics, namely Lactobacillus strains (L. crispatus, L. reuteri, L. casei and/or L. rhamnosus) administered orally or intravaginally, appear to improve HPV clearance and reduce cervical lesions.
Results remain mixed, with effects that vary by strain, duration and population, but some probiotics could still complement treatment and prevention strategies.

8

As of 2025, there are 8 licensed HPV vaccines, five of which have received WHO pre-qualification and are available globally.
All these protect against the high-risk HPV types 16 and 18, which cause ~76% of cervical cancers. 
This underscores the importance of vaccination in cervical cancer prevention and risk reduction. 2

Differences from one population to another

The composition of the vaginal microbiota varies across populations, and according to geographic origin, pregnancy, the menstrual cycle and age.
The dominant Lactobacillus species thus differ among Canadian, Chinese, Indian and Mexican women.
In cases of HPV, progression to cervical lesions and then cancer is associated with changes in the microbiota: among Mexican women, L. crispatus and L. iners predominate in women without disease, while Sneathia spp. appears in lesions and Fusobacterium in cervical cancer.

According to the authors, current research points to the need for additional studies, such as exploring how cervical cancer cultures respond to different Lactobacillus species.
The aim is to improve therapeutic treatment approaches and reverse dysbiosis to support recovery and even prevent these cervical cancers. 

Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News Off

Protein-rich or high-fiber: which breakfast is best for our gut microbiota?

Are you more of an eggs person or an oatmeal person in the morning? Researchers have tested two approaches in overweight adults. Weight loss, appetite, gut microbiota... the findings reveal some unexpected differences.
 

The gut microbiota

Breakfast is an essential meal for anyone seeking to lose weight or stay in shape.
But should we prioritize protein (dairy, eggs, ham, etc.), known for its satiating effect, or dietary fiber (oatmeal, whole-grain bread, fruit, etc.) which is beneficial for gut health?

50% Diet accounts for more than 50% of the variability of the microbiota. ¹

Hearty, balanced, but distinct

To try to find some answers, British researchers 2 put 19 overweight or obese adults on a balanced but low-calorie diet for 28 days. This diet was based on hearty breakfasts (45% of daily calories) and light dinners (a mere 20%).
For 28 days, each participant followed:

  • a high-fiber diet (30 g per day, with 15% of calories from protein)
  • then a high-protein diet (30% of calories from protein, with less than 15 g of fiber per day) 
  • or vice versa, with a washout period in between. 

The scientists measured changes in weight, satiety, blood markers, and more, and collected stool samples from the participants to analyze their microbiota. The results? 

The Mediterranean diet: good for the body, good for the heart

Learn more

Weight loss achieved

In both groups, weight loss was significant: nearly 5 kg in the fiber group and nearly 4 kg in the protein group. Blood pressure, fasting blood sugar, blood lipid levels, and other markers also decreased significantly, reflecting a marked improvement in the participants’ health.2
However, satiety was more pronounced in the protein group, suggesting that protein may be useful for regulating appetite outside of a diet or for sustaining energy levels during periods of restriction. 
And the gut microbiota? That’s a different story...

What is a “healthy” diet (according to the WHO)?

The WHO 3 emphasizes that rather than a single “model,” there are instead four principles: adequacy, balance, moderation, and diversity. 
In practice, a healthy diet mainly involves:

  • unprocessed or minimally processed and varied foods 
  • at least 400 g of fruits and vegetables per day (for those aged 10 and older); 
  • at least 25 g of fiber per day (for those aged 10 and older) from whole grains, legumes, fruits, and vegetables; 
  • less free sugar: ideally <10% of total energy intake (or even <5% for greater health benefits); 
  • higher-quality fats: limit saturated fats (<10%) and trans fats (<1%), and prioritize unsaturated fats (vegetable oils, fish, nuts)
     
Free sugar

Sugar added to foods/beverages (by the manufacturer, the cook, or you) plus sugar naturally present in honey, syrups, fruit juices, and juice concentrates.

Saturated fats

Fats found mainly in animal products (butter, cream, cheese, fatty meats) and also in certain vegetable fats (e.g., coconut/palm oil). Limit their intake. 

Trans fats

Industrially-modified fats (often through “hydrogenation”) found mainly in certain ultra-processed foods. The WHO recommends a very low intake.

Unsaturated fats

Fats found primarily in vegetable oils (olive, rapeseed, sunflower, etc.), nuts/seeds, and fatty fish. These are the fats that should replace saturated or trans fats.

Fiber, the microbiota’s ally

An analysis of bacterial strains showed that, compared to the fiber diet, the protein diet led to a significant loss of diversity and a decrease in the abundance of bacteria known for their beneficial effects: bifidobacteria and butyrate-producing bacteria, such as Faecalibacterium, Roseburia, and Anaerostipes. 

According to previous studies, this type of microbiota profile—which results from the fact that high-protein, low-fiber diets lead to a marked reduction in these bacteria and their beneficial metabolic products—is associated with an increased risk of several diseases. 

Key role of butyrate

Butyrate is a short-chain fatty acid ( (sidenote: Short chain fatty acids (SCFA) Short chain fatty acids (SCFA) are a source of energy (fuel) for an individual’s cells. They interact with the immune system and are involved in communication between the intestine and the brain. Silva YP, Bernardi A, Frozza RL. The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication. Front Endocrinol (Lausanne). 2020;11:25. ) ) that is important for maintaining good gut health. It serves as an energy source for gut cells, strengthens the gut barrier, and is believed to possess anti-inflammatory and anti-carcinogenic properties.
In practice, the high-protein breakfast was more effective at curbing appetite. However, the high-fiber breakfast was associated with a more “beneficial” microbiota, containing more bifidobacteria and butyrate-producing bacteria. So, which of the two is right for you?

Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News Off

Vaginal microbiome profiles provide clues about the risk of preterm birth

The presence of certain bacteria in the vaginal microbiota of pregnant women, combined with maternal characteristics such as age, may make it possible to stratify expectant mothers by obstetric risk and the risk of preterm birth.

Far from remaining static during pregnancy, the vaginal microbiota evolves, and this change has been previously linked to the risk of preterm labor and preterm birth.
Despite this, the links between vaginal microbiota and preterm birth are far from clear: studies to date have been single-center, with contradictory findings, perhaps due to a lack of adjustments for confounding factors, such as the mothers’ ethnic background.

To get a clearer picture, a study 1 study utilized data from the geographically and demographically diverse US birth cohorts in the ECHO (Environmental influences on Child Health Outcomes) program, which was designed to study the impact of prenatal and early neonatal exposures on child health. 

The researchers sought to use these cohorts to identify robust vaginal microbiota signatures during pregnancy which, when combined with maternal factors, could predict the risk of giving birth before 37 weeks of gestation.

<37 Preterm birth is defined as gestational age at birth of <37 weeks. ²

4-16% Across countries, the rate of preterm birth ranges from 4–16% of babies born in 2020. These findings illustrate the global scale of the risks associated with preterm birth. ²

13,4 million An estimated 13.4 million babies were born preterm worldwide in 2020. ²

Maternal factors associated to the risk of preterm birth

Of the 677 births analyzed, 12% (73) were preterm. The results show just how unequally women (mean age in study: 28 years) are affected by this risk.

  • For example, 84% of preterm births involved women who identified as Black,
  • and 85% were mothers with public health insurance only.

The risks of preterm labor and preterm birth thus appeared to be unevenly distributed according to maternal characteristics.

As regards the microbiota, women with a vaginal ( (sidenote: Community state types Five types of vaginal community have been identified, four dominated by lactobacilli (Lactobacillus crispatus, L. gasseri, L. iners, and L. jensenii) and a fifth characterized by a low lactobacilli content. ) ) dominated by lactobacilli other than L. iners were less affected by preterm birth. They accounted for 6.8% of preterm births and 28.8% of full-term births.

These findings suggest that a vaginal microbiota rich in Lactobacillus may be associated with greater vaginal stability during pregnancy.

900 000 Preterm birth complications are the leading cause of death among children under 5 years of age, responsible for approximately 900 000 deaths in 2019. ²

x3 Bacterial vaginosis is the most common lower genital tract infection and is associated with a 1.5- to 3-fold increase in risk for preterm labor. ¹

25-40% Up to 25–40 % of preterm births are considered infection-related. ¹

Bacteria at risk with predictive value

Risk assessments highlight an increased risk of preterm birth among women with diverse non-Lactobacillus-dominant vaginal communities, or vaginal communities dominated by L. iners, compared to women predominantly harboring L. crispatus , which is considered more stable. 

This holds true even after adjusting for ethnicity, maternal age, education level, or parity. 

The researchers subsequently tried to predict this risk by testing several models. The best model combined the taxa Gardnerella vaginalis (associated with bacterial vaginosis), Prevotella timonensis, and L. crispatus with maternal factors (age, ethnicity, etc.). It achieved an (sidenote: AUC (Area Under the Curve) A measure of a model’s ability to correctly distinguish between two classes (for example, “diseased” vs “healthy,” “positive” vs “negative”). It represents the area under a curve that plots the true positive rate (sensitivity) on the y-axis against the false positive rate on the x-axis. If the AUC equals 1, the model performs perfectly; above 0.80 it is generally considered very good, and above 0.90, excellent; at 0.5, it performs no better than random chance.
 
)
(area under the curve) of 0.77—a performance deemed satisfactory by the authors for a clinical prediction tool.

This study confirms that the vaginal microbiota, combined with maternal factors, could be used to create a predictive risk score for preterm birth across various US cohorts.

Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News Gynecology Off

Sunlight is reshaping the bacteria on your skin

We assume sunlight only affects the surface of our skin, tanning it, ageing it, burning it. But a new study reveals that UV rays also disturb the invisible community of bacteria living on your skin, and it happens within minutes.

The skin microbiota

Your skin is not a simple barrier; it is a living ecosystem. Millions of microorganisms, including bacteria, fungi, and viruses, make up your skin microbiome. Together, they help regulate your immune defences, strengthen protection against infections, and maintain the balance of your (sidenote: Cutaneous barrier The protective outer layer of skin that keeps harmful agents out and moisture in. The microbiome is a key living component of this barrier, disrupting the microbes means weakening the defence itself and reducing protection against environmental stressors. ) .
When this community is disturbed, the consequences can include inflammatory skin conditions such as atopic dermatitis or increased vulnerability to skin diseases.

UV radiation: not just a surface problem

We know that ultraviolet (UV) radiation damages the skin, it accelerates ageing, causes sunburn, and raises the risk of skin cancer with chronic exposure. What is less well understood is what it does to the microbial community living on the skin surface.
Researchers 1 at the Leibniz Research Institute for Environmental Medicine (Duesseldorf, Germany), set out to answer that question directly.
 

Skin microbiome

The community of bacteria, fungi, and other microorganisms that live on the surface of your skin. Far from being harmful, most of these microbes are essential partners that defend your skin, balance its immune responses, and help maintain a healthy (sidenote: Cutaneous barrier The protective outer layer of skin that keeps harmful agents out and moisture in. The microbiome is a key living component of this barrier, disrupting the microbes means weakening the defence itself and reducing protection against environmental stressors. ) They may also contribute to the production of compounds involved in barrier maintenance and cellular protection.

Disruption starts in as little as 30 minutes

In a controlled clinical trial, 30 healthy male volunteers were exposed to solar-simulated UVA and UVB radiation at three doses, 0.5, 0.7, and 1.0 minimal erythema dose (MED), on defined areas of the lower back.
Skin swabs were collected at:

  • 30 minutes,
  • 24 hours,
  • and 4 days after exposure and compared to non-irradiated control sites.

The results were clear: measurable changes in the skin microbiome were already detectable at 30 minutes, even at the lowest sub-erythemal dose, a level of UV that does not cause visible redness or sunburn.
The extent of microbial disruption was dose-dependent: the higher the UV dose, the more pronounced the shifts. Partial recovery was observed at 24 hours, but certain changes persisted at 4 days after irradiation, suggesting that exposed skin may retain a delayed microbial signature.

Sub-erythemal dose

 A level of UV radiation below the threshold needed to produce visible redness or sunburn. In this study, even these everyday, seemingly harmless doses were enough to alter the skin microbiome within 30 minutes.

What this means for your skin health

These findings matter because sub-erythemal UV doses are not exceptional, they represent ordinary, everyday sun exposure.
A short walk, time near a window, or an overcast day outdoors can all deliver these levels.
The study raises an important question about photoprotection: if sunscreen protects the skin from UV-induced cellular damage, could it also preserve the integrity of the skin microbiome and its immune protection?

Like to tan? Mind your skin microbiota!

Learn more

The researchers highlight this as a key area for future investigation and preventive strategies in dermatology. For now, the data suggest that protecting your skin from sun exposure goes deeper than visible damage, it extends to the microbial communities that keep your cutaneous barrier healthy. As summer approaches and sun exposure increases, these findings serve as a timely reminder.

Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News Off

When menstrual poverty threatens vaginal balance

In Kenya, menstrual poverty among sex workers appears to be associated with an imbalance in the vaginal microbiota and a higher presence of pathogenic bacteria. Reusable menstrual discs could help protect these women.

The vaginal microbiota

Among some women with high exposure to sexually transmitted infections (STIs), menstrual management can become a health issue, but also a matter of economic survival.
A study 1 conducted in Kenya highlights a little-documented phenomenon: the impact of menstrual poverty on the vaginal flora of sex workers.

When periods become an economic issue

In contexts of severe poverty, women do not have access to conventional menstrual products.
In Kenya, 42% of sex workers use makeshift solutions to continue seeing clients during their period. More than 9 out of 10 sex workers wipe the inside of their vagina with cloth, cotton or toilet paper between clients.

Unsafe intravaginal practices

Unsafe intravaginal practices examined:

  • using cloth, tissue, paper, or cotton to wipe inside the vagina to remove fluids between clients,
  • putting something inside the vagina before sexual intercourse to achieve a dry or tight sensation,
  • putting something inside the vagina to keep it dry during menses,
  • use of a commercial douche product,
  • and the frequency of wiping inside the vagina during menses, not during menses, and the difference between them (increased, decreased, or the same).

More fragile vaginal flora

In a large majority of these women, almost 2 out of 3, the vaginal microbiota is diverse, and therefore less protective compared with profiles in which lactobacilli dominate. It is associated with a higher risk of infections. Among the 407 women followed in this study:

  • 24.7% had acquired HIV,
  • 42.2% had bacterial vaginosis,
  • and 21.9% had chlamydia, gonorrhea or trichomoniasis,
  • only 20% had no infection.

In contrast, microbiota dominated largely by protective lactobacilli, especially Lactobacillus crispatus (CST-I), which were less common in these women, were associated with better vaginal health and fewer STIs or bacterial vaginosis.

30.7% HIV prevalence among sex workers was 30.7%, meaning a risk of HIV infection 11.6 times higher than in women in the general population. ¹

40% Among 1,640 female sex workers in Nairobi, Kenya, sex during menses was common, reported by 40%. ¹

72 72 million women worldwide must manage their menstruation without access to decent toilets. ²

Female anatomy, microbiotas and intimate hygiene

Learn more

The role of menstrual products

Monitoring these sex workers shows that use of unsuitable menstrual products seems to go hand in hand with changes in the vaginal microbiota, and even dysbiosis.
However, these results should be interpreted with caution: many factors are interconnected, including financial hardship, number of clients and working conditions, and the differences fade when these biases are taken into account.
Nevertheless, these trends are drawing researchers’ attention. Especially as certain pathogenic bacteria associated with bacterial vaginosis, such as Prevotella bivia or Mobiluncus curtisii, are more common among users of inadequate menstrual products.

Sub-optimal menstrual materials

Use of sub-optimal menstrual materials was defined as a composite of any use of cloth, cotton balls, or tissue during the last menstrual period.

Solutions still being explored

In response to these findings, researchers are exploring possible interventions. The idea is to improve access to suitable protection in order to improve vaginal health. Among the solutions being studied are flexible menstrual discs, which can be worn during sexual intercourse and used over the long term, for up to 10 years, which could reduce costs, limit certain risky practices and improve these women’s comfort and intimate hygiene.

Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News Off

How reliable are at-home gut microbiome tests?

Since gut microbiota appears to be linked to our health, many of us may be tempted to take a home test to learn more about the tiny world it harbors. This test may seem like an appealing way to explore one’s gut flora, its diversity and its microbiota. But the reliability of such tests leaves a lot to be desired…

The gut microbiota
Kit de test du microbiote intestinal à domicile pour connaître son microbiote

After the genetic testing trend, a new wave of self-testing is emerging: gut microbiome tests.
The idea is simple: analyze the bacteria present in your intestines from a stool sample collected using a testing kit and sent by mail.

27% Around 1 in 4 people surveyed (27%) had already heard about microbiome testing. ¹

60% 6 out of 10 respondents would be willing to have their gut microbiota tested as part of a general health checkup (61%), while 23% would do so out of curiosity. ¹

You directly receive a “gut health profile,” without having to see a doctor, to detect any potential dysbiosis. In other words, these bacteria are used as indicators thought to reflect the balance of the gut flora. 
A booming market driven both by recent scientific discoveries highlighting the links between the microbiota and various digestive and metabolic diseases, such as obesity or certain cancers, as well as mental health disorders, but also its essential role in immune system development—not to mention the misinformation spread on social media.
All in a climate of confusion between at-home self-tests and research on medical tests in clinical settings.

+7.7% per year

The global self-testing market (all tests combined) was valued at $21.9 billion in 2025.
It is expected to grow from $23.7 billion in 2026 to $46.1 billion in 2035, representing an annual growth rate of 7.7%. 2

Unreliable results

Are these at-home tests reliable? A team of researchers 3 set out to check this by evaluating seven commercial services. To do this, they used a standardized stool sample—the kind laboratories typically use as a reference—and sent it three times to each company, using each complete kit according to the provided instructions, just as a consumer would before sending it to the lab.

The results should discourage you from investing in these tests! There are many flaws:

  • analytical methods vary significantly from one company to another at every stage, from sample collection procedures to the computer-based analysis of results and the assessment of gut microbiota composition.
  • results vary significantly from one company to another: only one bacterial genus (Streptococcus) was found by all companies. In some cases, the differences were comparable to the natural variations seen between individuals! Even more surprising, a same company sometimes obtained different results from the same sample sent three times for analysis.
  • regarding result interpretation, each company uses its own benchmarks. The result: findings can vary from one provider to another—or even within a same company, which may deem a same profile “healthy” in one analysis and “unhealthy” in the next! This leads to contradictory recommendations, which are nonetheless presented as “personalized” in the report provided to consumers.

20% Only 2 out of 10 respondents (20%) would have their gut microbiota tested to help balance their microbiota, or to prevent or slow the progression of disease. ¹

31% 3 out of 10 participants (31%) would be willing to have their microbiota tested to help advance microbiota science. ¹

Call for caution and improvement

These discrepancies pose a serious problem, with the risk of delayed diagnosis for patients seeking answers, who might self-medicate based on misinformation, particularly when trying to better understand certain illnesses or a persistent intestinal disorder.

It is important to remember that age, diet, lifestyle and use of medications or probiotics all have a significant impact on the microbiota. Since these numerous factors are constantly changing, at-home microbiome tests taken at a single point in time cannot reliably determine whether microbiota is “good” or “bad,” nor can they yield relevant medical conclusions.

Furthermore, as consumer demand continues, the study’s authors are calling for several improvements to ensure that a simple test kit result is not treated as a medical diagnostic tool:

  • improve analytical quality,
  • exercise caution when interpreting results,
  • and establish common guidelines for the entire sector (from testing companies to all potential partners involved).

The aim: to standardize practices and restore confidence among both users and health authorities.

Self-testing vs. medical testing: do not confuse the two!

There are two types of microbiome tests available on the market, and they should not be confused: direct-to-consumer tests (self-tests or at-home tests), and traditional diagnostic tests performed in a medical setting.
This distinction is based on several key points:

  • how data is collected and accessed: at-home tests allow consumers to collect their own samples, send them to a laboratory, and access the results without the involvement of a clinician. In contrast, traditional medical tests are performed by trained healthcare professionals.
  • level of regulatory oversight: at-home tests are not subject to the same level of oversight as traditional medical diagnostic tests when it comes to the validation of their analytical performance. Self-tests fall somewhere between strictly regulated medical devices and general wellness products, which are subject to much less regulation.
  • clinical validation: unlike tests conducted in a medical setting, where validation is crucial to ensuring the reliability of results for clinicians and patients, at-home tests often lack the validation necessary for sound clinical decision-making.
  • current regulatory status: as of early 2026, no clinical microbiome diagnostic test is approved by regulatory authorities in the United States, and the only sequencing-based test with CE marking in Europe is publicly discouraged by the French Society of Microbiology.

At-home tests are therefore considered “personal wellness” services that, unlike medical tests, are not subject to the analytical and clinical validation standards required for them to be reliable diagnostic tools. In response to these self-tests, microbiota researchers and clinicians urge the utmost caution. 

Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News Off

At-home gut microbiome tests: patients should exercise caution

The results and interpretations of at-home gut microbiome tests vary so widely from one company to another that their reliability and clinical utility are widely questioned.

Mental health disorders, cancer, obesity: human gut microbiota has been linked to numerous diseases since the early 2000s. Thanks to extensive media coverage, studies are encouraging consumers to “test” their gut health. A potentially lucrative market for sellers of self-test kits: consumers collect a stool sample at home, send it to the lab and receive the results directly.

+7.7% per year

The global self-testing market (all tests combined) was valued at $21.9 billion in 2025.
It is expected to grow from $23.7 billion in 2026 to $46.1 billion in 2035, representing an annual growth rate of 7.7%. 1

7 self-tests under scrutiny

A team 2 compared the performance of seven gut microbiome testing services by submitting three replicates of a standardized human stool sample to each, the kind laboratories typically use for calibration.

First observation: microbiome testing methods vary greatly between companies (collection procedures, sequencing, analysis), with no common standard. 

27% Around 1 in 4 people surveyed (27%) had already heard about microbiome testing. ³

60% 6 out of 10 respondents (60%) would be willing to have their gut microbiota tested as part of a general health checkup (60%), while 23% would do so out of curiosity. ³

Second limitation: results vary significantly from one company to another.

  • Of the seven companies tested, three detected the presence of Clostridioides difficile in the standardized sample, while the other four reported it as absent.
  • Only one genus (Streptococcus) showed consistent results across all methods, while Roseburia showed the greatest discrepancy.
  • In some cases, differences in results for a same sample exceeded the biological variations seen between individuals!
  • Finally, the same company sometimes reported inconsistent results after analyzing the same standard sample three times. 

20% Only 2 out of 10 respondents (20%) would have their gut microbiota tested to help balance their microbiota, or to prevent or slow the progression of disease. ³

31% 3 out of 10 participants (31%) would be willing to have their microbiota tested to help advance microbiota science. ³

A final challenge: interpretation of results.
Because there is no universal definition of a healthy microbiota, each company uses its own reference values for several key bacteria. As a result, the findings vary from one company to another.
Worse still: within a same company, results can vary across replicates, sometimes leading to conflicting recommendations (with the microbiota deemed “healthy” or “unhealthy” depending on the replicate). These differences—both between and within companies—lead to inconsistent health interpretations and advice.

Diversity or function: what defines a healthy microbiota

Learn more

The authors’ recommendations

Recognizing the demand from patients seeking answers to their health issues, the authors recommend two main areas for improvement:

  • Improve clinical validity by consistently citing the literature for each health interpretation to justify statements and recommendations, and distinguishing between simple correlations and true causal relationships.
  • Strengthen analytical performance and transparency through quality control standards (reference materials, known microbial communities, minimum detection limits).

They also emphasize the need to develop common guidelines for the industry, drawing on best practices from other diagnostic fields, in order to harmonize practices and build confidence among users and regulatory authorities.

Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News Gastroenterology Off

The air you breathe is changing your mouth microbiome

You think of pollution as something that hurts your lungs. But a new study suggests ozone rewrites the tiny community of microbes living in your mouth first, and those oral bacteria may be quietly steering how well you breathe. 

The pulmonary microbiota

Your mouth is home to hundreds of bacterial species, a bustling invisible city that does far more than freshen breath. It shapes how your immune system reacts and, because the mouth opens straight into the airways, it shapes the lungs that sit just below. Chinese researchers 1 wanted to know what happens to that city when ozone, the sharp, sunlit pollutant rising over our urban skies, drifts in.

A two-hour ozone, and everything shifts

Twenty-nine healthy young adults spent two hours inside a sealed chamber, breathing either filtered air or ozone at roughly the level of a bad summer smog day. Two weeks later, they switched. Nobody knew which air they were getting.
The difference was striking: after the ozone session, lung power dropped sharply, the volume of air the participants could forcefully exhale fell by around 12%, and the speed of that exhale by 14%.
That is not abstract. That is the feeling of climbing stairs and noticing, for the first time, that you are counting them.

Ozone

An invisible, reactive gas that forms when sunlight hits vehicle and industrial emissions. High up in the atmosphere it protects us from UV rays; down at street level, it becomes an irritating pollutant that can slip into the mouth and lungs and trigger damage.

The clue is in your mouth

Then the scientists swabbed cheeks and throats. Ozone had thinned the oral microbial community by more than a fifth, whole species, simply gone after a single exposure.
One bacterium, called Treponema medium, more than doubled its numbers and stood out as the clearest fingerprint of ozone damage. Its rise tracked closely with the drop in breathing capacity, suggesting the mouth is not just a bystander but a messenger, carrying signals of pollution downward into the lungs.

Oral microbiome

The living community of bacteria, fungi and viruses that coats your cheeks, gums, tongue and throat. Far from being uninvited guests, they help shape your immunity and sit at the doorway to your lungs, which is why changes there can ripple downwards into your breath.

Why men felt it harder

Curiously, the men in the trial took the bigger hit. Their lung scores fell; the women's barely moved.
Their oral microbes reshuffled more dramatically too. The reasons are still being pieced together, but animal studies hint at sex-specific immune wiring that makes male airways more reactive to oxidising gases. However, as the female subgroup was smaller, these sex differences need confirmation.
The takeaway is not panic, it is perspective.
The air you cannot see is having conversations with the organisms you cannot feel, and those conversations are rewriting your breath.

Exposome: exposed microbiota puts health at risk

Learn more
Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News Off

When a diverse vaginal microbiome is the wrong answer

We are told a diverse microbiome is a healthy one. But a new Italian study 1 flips that rule for the vagina: the more varied the bacteria down there, the more antibiotic resistance genes they carry, and your daily habits tip the balance.

The vaginal microbiota

Inside every woman's body, a small, mostly invisible community of bacteria lives in balance in the vagina. When it's dominated by lactobacilli, it guards against infection like a tightly packed hedge keeping weeds out.
Italian researchers wanted to know something new about that hedge: is it also quietly storing genetic instructions for resisting antibiotics, and if so, what in your daily life is feeding that archive?

𝘓𝘢𝘤𝘵𝘰𝘣𝘢𝘤𝘪𝘭𝘭𝘶𝘴 𝘤𝘳𝘪𝘴𝘱𝘢𝘵𝘶𝘴

A particular lactobacillus species considered the gold standard for vaginal health. When it dominates, it produces acids that lower the vaginal pH, making the environment unfriendly to many infection-causing microbes.

A résumé written in your bacterial DNA

The team asked 105 healthy young women to self-collect their vaginal microbiome with swabs, none of them pregnant, none on antibiotics in the past month, and hunted for 14 different resistance genes.
The result was striking. Five of those genes, including ones that shield bacteria from two of our most-prescribed antibiotic families, erythromycin-type (like erm(F)) and tetracycline-type (like tet(M)), showed up in more than two-thirds of participants.
Most women were unknowingly walking around with a small dossier of instructions for shrugging off common antibiotics, tucked inside bacteria they had never thought about.

Antibiotics: what impact on the microbiota and on our health?

Learn more

When more diversity means less health

Here the story flips what many of us assume. In the gut, a diverse microbiome usually means a healthy one. In the vagina, the opposite tends to be true: a thriving single bacterial species, Lactobacillus crispatus, is the sign of balance.

The researchers found that :

  • the more crowded and mixed the vaginal community became, the more it drifted toward Gardnerella, Prevotella and other dysbiosis-linked bacteria, the more resistance genes accumulated.
  • By contrast, L. crispatus was associated with fewer resistance genes, almost like a gatekeeper turning them away.

The everyday choices the genes respond to

What made the gene count climb? Smoking tripled the odds of carrying one specific resistance gene.
A higher body weight nudged the numbers up. A vaginal yeast infection was linked to almost four times the overall resistance score. Even unused antibiotics from the past year left a trace.
What seemed to push back? Oral contraceptives, a Mediterranean-style diet, and simply understanding how antibiotics work and why finishing the course matters.

Your vaginal microbiome is not a sealed room. It listens to your kitchen, your pharmacy and your lungs.
The good news is that much of what it hears, you choose.

Practices that put your vaginal microbiota at risk

Learn more
Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News Off

Immunotherapies: a Phase II study confirms the benefit of combined FMT

A new step in the evaluation of FMT to improve response to immunotherapies: a Phase II study confirms its effectiveness, with the transplant helping eliminate bacteria linked to poor treatment response. 1

Photo: Immunotherapies: a Phase II study confirms the benefit of combined FMT

(sidenote: Immune checkpoint inhibitors (ICIs) Therapies that seek to remove the mechanisms that inhibit the immune system’s response to cancer cells. Targeted checkpoints include Programmed Death-1 (PD-1), Programmed Death-Ligand 1 (PDL-1), and cytotoxic T-lymphocyte associated protein 4 (CTLA-4). Lifting these brakes allows the immune system to recognize and attack cancer cells.
 
)
(ICI) have improved the prognosis of non-small cell lung cancer (NSCLC) and cutaneous melanoma, but more than half of patients remain resistant.

Fecal microbiota transplant (FMT) could help overcome resistance to (sidenote: Anti-PD-1 immunotherapy based on immune checkpoint inhibitors that target the PD-1 checkpoint, reversing the deactivation by the tumor of the recognition system associated with the PD-1 protein present on the surface of T lymphocytes. The immune system’s effectiveness against tumor cells is thus restored. ) : successful mouse trials, two Phase I clinical trials providing initial proof of concept, then the MIMIC Phase I trial demonstrating the safety of FMT from healthy donors to reduce primary resistance to anti-PD-1 treatment in patients with cutaneous melanoma.

1st Lung cancer is the leading cause of cancer cases and deaths worldwide with an estimated 2.5 million new cases and 1.8 million deaths in 2022. ²

2 The 2 main types of lung cancer are non-small cell lung cancer (NSCLC), which accounts for around 85% of cases, and small cell lung cancer (SCLC), which is less common but typically more aggressive. ²

39-45% Patients with NSCLC are treated with single-agent anti-PD-1 such as pembrolizumab, with an expected objective response rate (ORR) of 39−45%. ¹

Confirmed efficacy in Phase II

Hence the interest in the multicenter Phase II FMT-LUMINate trial, evaluating FMT from healthy donors combined with anti-PD-1 monotherapy in NSCLC (n = 20) or with dual immunotherapy (anti-PD-1 + (sidenote: Anti-CTLA-4 immune checkpoint inhibitor that targets the CTLA-4 checkpoint ) ) in cutaneous melanoma (n = 20). Eligible patients received one dose of FMT before immunotherapy. Ten healthy volunteer donors (10 in the NSCLC cohort, 6 in the melanoma cohort) provided stool samples.

The results demonstrate the clinical efficacy of FMT:

  • for NSCLC, combined with anti-PD-1 therapy, the (sidenote: Objective response rate (ORR) Proportion of responding patients (who showed a complete or partial response), as opposed to patients with stable disease or disease progression. ) was 80% (16 of 20 patients), exceeding the predefined primary objective of 64%. Without FMT, ORR ranges from 39 to 45%.
  • for melanoma, combined with anti-PD-1 and anti-CTLA-4, ORR was 75% (15/20) vs. 50–58% without FMT.

The disappearance of harmful bacteria

After FMT, patients’ gut microbiota was modified, without strong similarity to the donor. More importantly, the authors show that the clinical response is not related to the acquisition of new bacteria from the donor; it depends mainly on the disappearance of bacteria present in the patient before treatment, including species such as Enterocloster citroniae, E. lavalensis and Clostridium innocuum. Enterocloster and Clostridium spp. are known to be associated with poor response to immunotherapy and sometimes with unfavorable inflammatory profiles.

This loss of certain bacteria changes microbial metabolism, reducing tryptophan pathways involved in immunosuppression, and creates a more favorable immune environment with more cytotoxic T cells and fewer regulatory cells.

17th Skin melanoma is the 17th most common cancer and the 22nd leading cause of cancer death worldwide, with an estimated 332,000 new cases and 59,000 deaths in 2022. ³

50−58% In patients with melanoma, dual therapy with ipilimumab (anti-CTLA-4) in combination with nivolumab (anti-PD-1) is among the most commonly used frontline regimens, yielding an ORR of 50−58%. ¹

Safety assessment of FMT

In terms of safety, FMT was well tolerated in patients with NSCLC receiving anti-PD-1, with no adverse events of grade ≥3.

However, in the melanoma cohort receiving dual immunotherapy, adverse events were observed in 65% of patients, as well as a higher-than-expected rate of myocarditis in those who received FMT from a donor whose microbiota was enriched with Prevotella, including (sidenote: Segatella copri Segatella copri: formerly named Prevotella copri clade A., P. copri is not a single homogeneous species but a complex made up of 4 distinct genetic lineages (clades A, B, C, and D) with strong functional diversity. These lineages are often found together in non-Westernized populations (presence of all 4 clades, sometimes except D) but are much less frequent in Westernized populations (presence of A and B, A, or none). The decline of P. copri in Western-lifestyle populations may be linked to lifestyle and dietary changes associated with modernization. Source: Tett A, Huang KD, Asnicar F et al. The Prevotella copri Complex Comprises Four Distinct Clades Underrepresented in Westernized Populations. Cell Host Microbe. 2019 Nov 13;26(5):666-679.e7. ) . These adverse events were not seen in NSCLC patients treated with anti-PD-1 alone and receiving FMT from the same donor. This suggests an interaction between microbial taxa (involving Prevotella) and the type of immunotherapy (dual PD-1/CTLA-4).

Another lesson can thus be drawn from the study: selecting healthy donors is essential and remains to be defined.

Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News Oncology Pulmonology Dermatology Off